WO2002098435A1 - Composiciones orales para el tratamiento de mamíferos obesos y no diabéticos, incluyendo humanos - Google Patents
Composiciones orales para el tratamiento de mamíferos obesos y no diabéticos, incluyendo humanos Download PDFInfo
- Publication number
- WO2002098435A1 WO2002098435A1 PCT/ES2002/000231 ES0200231W WO02098435A1 WO 2002098435 A1 WO2002098435 A1 WO 2002098435A1 ES 0200231 W ES0200231 W ES 0200231W WO 02098435 A1 WO02098435 A1 WO 02098435A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- obesity
- rats
- tungstate
- including humans
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Definitions
- the invention relates to the use of oral compositions for the treatment of non-diabetic mammals suffering from obesity and / or overweight, including humans.
- the active ingredients of these compositions are compounds that have never been suggested for that use, although some of them are chemically known.
- Obesity / overweight is a chronic metabolic disorder in which excess body fat causes or increases the risk of health problems. In particular, it is associated with coronary heart disease, the development of certain forms of cancer, respiratory problems and cholelithiasis. It is a complex disorder determined by interactions between genetic, environmental and psychosocial factors that affect the balance between intake and energy expenditure.
- Human obesity defined as a body mass index greater than 30 Kg / m 2 , is an important and expensive disease in developed countries, with an approximate prevalence of 15-20% in Europe and 20-25% in the USA. . However, it is also present, and growing, in Latin America, Southeast Asia and the Middle East. Despite the importance of obesity as a medical and social problem, no fully effective treatment is available today.
- US Patent 5,595,763 describes the use of tungsten (VI) compositions as insulin-mimetic drugs for the treatment of mammals suffering from diabetes ellitus, including humans. Although mammals, including humans, who suffer from type 2 diabetes
- non-insulin-dependent diabetes mellitus can also show symptoms of obesity, the two pathologies (diabetes and obesity) are considered clinically different from each other. Actually, many human beings who suffer from obesity are never considered diabetic.
- the present invention specifically relates to the treatment of obesity in the population of patients who are obese and non-diabetic. Tungsten compounds have never been suggested for such treatment.
- an oral composition for the prophylactic, therapeutic and / or cosmetic treatment of obesity / overweight in non-diabetic mammals, including human, said composition comprising an effective amount of a compound formed by tungsten (VI) and a pharmaceutically acceptable chemical part, or of a solvate of said compound, in combination with pharmaceutically acceptable excipients.
- a compound formed from tungsten (VI) and a pharmaceutically acceptable chemical moiety is intended to include any chemical entity formed by one or more tungsten atoms in their oxidation state 6+, which is bound to a pharmaceutically acceptable chemical structure by itself.
- the 6 * cation has neither been observed nor isolated, and is always accompanied by a chemical part partially formed by a coordination sphere around the atom of W (VI).
- the coordination sphere can be formed by inorganic ligands (oxide, hydroxide, peroxide, etc.) such as, for example, in the case of the tungstate anion (with a coordination sphere formed by four oxide ions), or in the case of peroxitungstatos (with coordination spheres formed by mixtures of oxide and peroxide ions).
- the coordination sphere may also be formed by organic ligands that are molecules or ions attached to the W (VI) atom through O, S or N atoms belonging to different pharmaceutically acceptable organic compounds (eg carboxyls, amines, amino acids, nitrogen heterocycles, etc.). Inorganic / organic mixed coordination spheres are also possible.
- the term "chemical part” also includes any pharmaceutically acceptable ionic species that neutralizes the tungsten compound (VI) as a whole.
- the anion Tungstate is always accompanied by a cation (eg Sodium, potassium, magnesium, calcium), forming a neutral tungstate salt.
- the tungstate ion originates a series of isopolitungstates (paratungstates, metatungstates, etc.) that differ in the degree of aggregation; its use is also contemplated in this invention.
- Solvates of tungsten (VI) compounds eg sodium tungstate dihydrate
- their use is also considered part of this invention.
- Another aspect of the present invention relates to the use of a compound formed by tungsten (VI) and a pharmaceutically acceptable chemical part, or of a solvate of said compound, for the preparation of an oral composition, for prophylactic, therapeutic and / or treatment. or cosmetic obesity / overweight in non-diabetic mammals, including humans.
- the invention also relates to a method of prophylactic, therapeutic and / or cosmetic treatment of non-diabetic mammals suffering from obesity / overweight, including humans, said method comprising oral administration of an effective amount of a compound formed by tungsten (VI) and a pharmaceutically acceptable chemical part, or a solvate of said compound, in combination with pharmaceutically acceptable excipients.
- a compound formed by tungsten (VI) and a pharmaceutically acceptable chemical part, or a solvate of said compound in combination with pharmaceutically acceptable excipients.
- the tungsten compound (VI) in the pharmaceutical composition of this invention is a tungstate salt.
- the salts of cationic parts selected from the group consisting of sodium, potassium, magnesium and calcium cations.
- Sodium tungstate dihydrate is a white and odorless salt, with a fine and crystalline texture, and easily dissolves in water.
- the product can be administered orally by any conventional galenic form, the tablet being the preferred form.
- the preferred daily dose of sodium tungstate dihydrate is between 0.5 and 50 mg / kg.
- Fig. 1 shows the evolution of the increase in body weight ( ⁇ in kilograms) over time (t in days) throughout the first 30 days of the study, both for standard diet rats (dashed line) and for rats cafeteria diet (continuous line).
- Fig. 2 shows the evolution of the increase in body weight ( ⁇ in kilograms) over time (t in days) throughout the three periods of the experiment, namely: induction of obesity (between day 0 and + W), treatment with tungstate (between + and -W), and recovery (between -W and the end).
- EXAMPLE 1 Feeding the rats used in the experiment: standard diet versus cafeteria diet
- the so-called "cafeteria diet” consists of offering fresh and tasty foods high in fat and / or carbohydrates, along with standard laboratory feed. It is known that rats fed a cafeteria diet significantly increase their energy intake (as much as 60%) and their body weight gain (50-200%), when compared to animals fed only with standard feed. In addition, it is also known that ingestion of cafeteria diet results in an increase in thermogenesis and fat deposition.
- male istar rats IFFA CREDO
- IFFA CREDO male istar rats
- weighing 0.20-0.22 kg in a 12-12 h light-dark cycle, and in an environment of controlled temperature and humidity were individually caged.
- the animals were divided into two feeding groups.
- One group was fed a standard feed diet (2.7% fat content, type A04 from Panlab, Barcelona, Spain); and the second group was fed a cafeteria diet (30% fat content).
- the cafeteria diet consisted of the daily offer in cookies, liver pate, bacon of pork, standard feed and whole milk supplemented with 333 g / 1 of sugar and 10 g / 1 of a mineral and vitamin complex (Gevral, Cynamid Ibérica, Madrid, Spain). All foods were weighed and presented in excess.
- the treatment was carried out for 32 days. Blood glucose measurements and blood samples were taken before (days 0-30), during (days 31-62) and at the end of the experimental period. Daily selective feed intake (corrected for the amount of water lost by each) and the weight of all animals were recorded.
- TAMi intercapular brown adipose tissue
- TAB white adipose tissue
- the remaining rats (n 19) were treated with tungstate, but the feeding conditions were maintained, in order to begin a recovery period of 35 days. After this time the animals were slaughtered and processed as indicated before. Daily selective feed intake (corrected for the amount of water lost by each) and the weight of all animals were recorded.
- FIG. 1 shows the evolution of the increase in weight ( ⁇ in kilograms) over time (t in days) throughout the first 30 days of the experiment, both for standard feed rats (dashed line) and for feed rats cafeteria (continuous line).
- FIG. 2 shows the evolution of the increase in body weight ( ⁇ in kilograms) over time (t in days) throughout the three periods of the experiment, namely: the period of induction of obesity (from day 0 to day 30, the latter marked with +), the tungstate treatment period (from day 31 to day 62, the latter marked with -W), and the recovery period (from day 63 to day 97).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002447141A CA2447141A1 (en) | 2001-05-16 | 2002-05-16 | Oral compositions for the treatment of non-diabetic obese mammals, including humans |
EP02732763A EP1400246B1 (en) | 2001-05-16 | 2002-05-16 | Oral compositions for the treatment of obese, non-diabetic mammals, including humans |
ES02732763T ES2275873T3 (es) | 2001-05-16 | 2002-05-16 | Composiciones orales para el tratamiento de mamiferos obesos y no diabeticos incluyendo humanos. |
BR0210975-1A BR0210975A (pt) | 2001-05-16 | 2002-05-16 | Composição oral para uso como um agente profilático, terapêutico e/ou cosmético para a obesidade/excesso de peso em mamìferos não diabéticos, inclusive em seres humanos e preparação de uma composição oral |
US10/477,807 US7122209B2 (en) | 2001-05-16 | 2002-05-16 | Oral compositions for the treatment of non-diabetic obese mammals, including humans |
DE60215812T DE60215812T2 (de) | 2001-05-16 | 2002-05-16 | Orale zusammensetzungen zur behandlung von adipösen, nicht diabetischen säugetieren, einschliesslich menschen |
DK02732763T DK1400246T3 (da) | 2001-05-16 | 2002-05-16 | Orale sammensætninger til behandling af adipöse, ikke-diabetiske pattedyr, indbefattet mennesker |
CY20071100138T CY1105975T1 (el) | 2001-05-16 | 2007-01-31 | Στοματικες συνθεσεις για την θepαπεια παχυσαρκων, μη διαβητικων θηλαστικων, πepιλαμβανομενων των ανθρωπων |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP200101200 | 2001-05-16 | ||
ES200101200A ES2187276B1 (es) | 2001-05-16 | 2001-05-16 | Composiciones orales para el tratamiento de humanos obesos y no diabeticos. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002098435A1 true WO2002098435A1 (es) | 2002-12-12 |
Family
ID=8497838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2002/000231 WO2002098435A1 (es) | 2001-05-16 | 2002-05-16 | Composiciones orales para el tratamiento de mamíferos obesos y no diabéticos, incluyendo humanos |
Country Status (11)
Country | Link |
---|---|
US (1) | US7122209B2 (es) |
EP (1) | EP1400246B1 (es) |
AT (1) | ATE344042T1 (es) |
BR (1) | BR0210975A (es) |
CA (1) | CA2447141A1 (es) |
CY (1) | CY1105975T1 (es) |
DE (1) | DE60215812T2 (es) |
DK (1) | DK1400246T3 (es) |
ES (2) | ES2187276B1 (es) |
PT (1) | PT1400246E (es) |
WO (1) | WO2002098435A1 (es) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007014970A1 (es) * | 2005-07-29 | 2007-02-08 | Universidad De Barcelona | Composiciones farmacéuticas que comprenden una sal de tungsteno (vi) para el tratamiento de trastornos neurodegenerativos, en particular alzheimer y esquizofrenia |
CN100515428C (zh) * | 2007-04-26 | 2009-07-22 | 暨南大学 | 钨酸锂在制药中的应用 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006062250A1 (de) * | 2006-12-22 | 2008-06-26 | Roland Saur-Brosch | Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden |
ES2478790B1 (es) * | 2013-01-22 | 2015-05-06 | Oxolife, S. L. | Uso de sales de tungsteno (VI) para el tratamiento de la infertilidad femenina en mamíferos no diabéticos |
ES2551828B1 (es) * | 2014-05-21 | 2016-09-12 | Oxolife S.L. | Composiciones alimentarias que comprenden sales de tungsteno (VI) |
PT3173382T (pt) * | 2014-07-21 | 2023-03-10 | Oxolife Sl | Sais de tungsténio (vi) utilizados para tratar infertilidade, para estimular a fertilidade e a reprodução normal num mamífero fêmea não diabético, e para melhorar a eficácia das técnicas de reprodução assistida |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6025928A (ja) * | 1983-07-21 | 1985-02-08 | Tanaka Seinosuke | 薬剤 |
ES2108642A1 (es) * | 1995-07-26 | 1997-12-16 | Quimica Farm Bayer Sa | Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus. |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4018513C1 (es) * | 1989-12-20 | 1991-05-08 | Karl Oexmann, Inh. Wolfgang Oexmann, 4650 Gelsenkirchen, De | |
US5192197A (en) * | 1991-11-27 | 1993-03-09 | Rockwell International Corporation | Piezoelectric pump |
CH689836A5 (fr) * | 1994-01-14 | 1999-12-15 | Westonbridge Int Ltd | Micropompe. |
US5611214A (en) * | 1994-07-29 | 1997-03-18 | Battelle Memorial Institute | Microcomponent sheet architecture |
US5595763A (en) * | 1995-07-19 | 1997-01-21 | Quimica Farmaceutica Bayer S.A. | Tungsten (VI) compositions for the oral treatment of diabetes mellitus |
US6148635A (en) * | 1998-10-19 | 2000-11-21 | The Board Of Trustees Of The University Of Illinois | Active compressor vapor compression cycle integrated heat transfer device |
-
2001
- 2001-05-16 ES ES200101200A patent/ES2187276B1/es not_active Expired - Fee Related
-
2002
- 2002-05-16 AT AT02732763T patent/ATE344042T1/de not_active IP Right Cessation
- 2002-05-16 ES ES02732763T patent/ES2275873T3/es not_active Expired - Lifetime
- 2002-05-16 EP EP02732763A patent/EP1400246B1/en not_active Expired - Lifetime
- 2002-05-16 DK DK02732763T patent/DK1400246T3/da active
- 2002-05-16 US US10/477,807 patent/US7122209B2/en not_active Expired - Fee Related
- 2002-05-16 PT PT02732763T patent/PT1400246E/pt unknown
- 2002-05-16 BR BR0210975-1A patent/BR0210975A/pt not_active IP Right Cessation
- 2002-05-16 DE DE60215812T patent/DE60215812T2/de not_active Expired - Fee Related
- 2002-05-16 CA CA002447141A patent/CA2447141A1/en not_active Abandoned
- 2002-05-16 WO PCT/ES2002/000231 patent/WO2002098435A1/es active IP Right Grant
-
2007
- 2007-01-31 CY CY20071100138T patent/CY1105975T1/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6025928A (ja) * | 1983-07-21 | 1985-02-08 | Tanaka Seinosuke | 薬剤 |
ES2108642A1 (es) * | 1995-07-26 | 1997-12-16 | Quimica Farm Bayer Sa | Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus. |
Non-Patent Citations (3)
Title |
---|
DATABASE WPI Week 198512, Derwent World Patents Index; AN 1985-071661, XP002019717 * |
FOSTER J.D. ET AL.: "Tungstate: a potent inhibitor of multifunctional glucose-6-phosphatase", ARCHIV. BIOCHEM. BIOPHYS., vol. 354, no. 1, 1998, pages 125 - 132, XP002958356 * |
MATSUMOTO J.: "Vanadate, molybdate and tungstate for orthomolecular medicine", MEDICAL HYPOTHESES, vol. 43, 1994, pages 177 - 182, XP000610418 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007014970A1 (es) * | 2005-07-29 | 2007-02-08 | Universidad De Barcelona | Composiciones farmacéuticas que comprenden una sal de tungsteno (vi) para el tratamiento de trastornos neurodegenerativos, en particular alzheimer y esquizofrenia |
EP1972342A1 (en) * | 2005-07-29 | 2008-09-24 | Universidad De Barcelona | Pharmaceutical compositions comprising a tungsten salt (vi) for the treatment of neurodegenerative disorders, particularly alzheimer's disease and schizophrenia |
EP1972342A4 (en) * | 2005-07-29 | 2011-01-12 | Univ Barcelona | PHARMACEUTICAL TREATED SALT (VI) COMPOSITIONS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDERS, IN PARTICULAR ALZHEIMER DISEASE AND SCHIZOPHRENIA |
CN100515428C (zh) * | 2007-04-26 | 2009-07-22 | 暨南大学 | 钨酸锂在制药中的应用 |
Also Published As
Publication number | Publication date |
---|---|
ES2187276B1 (es) | 2004-08-01 |
DE60215812T2 (de) | 2007-08-30 |
ES2275873T3 (es) | 2007-06-16 |
CY1105975T1 (el) | 2011-04-06 |
CA2447141A1 (en) | 2002-12-12 |
DK1400246T3 (da) | 2007-03-05 |
US20040131697A1 (en) | 2004-07-08 |
ES2187276A1 (es) | 2003-05-16 |
PT1400246E (pt) | 2007-02-28 |
EP1400246B1 (en) | 2006-11-02 |
EP1400246A1 (en) | 2004-03-24 |
US7122209B2 (en) | 2006-10-17 |
DE60215812D1 (de) | 2006-12-14 |
BR0210975A (pt) | 2004-10-05 |
ATE344042T1 (de) | 2006-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2592803T3 (es) | Formulación farmacéutica que comprende compuestos de lantano | |
ES2310417T3 (es) | Procedimiento para tratar la insuficiencia renal. | |
PT1827386E (pt) | Composições orais para a absorção de compostos de fósforo | |
ES2941460T3 (es) | Composición y método para mejorar la curación de heridas | |
CA2767833A1 (en) | N-acetyl cysteine compositions and methods to improve the therapeutic efficacy of acetaminophen | |
JP2004530659A (ja) | 抗腫瘍および抗転移作用のための方法および処方 | |
CA2788865A1 (en) | Composition comprising as active ingredient l-carnitine in combination with hydroxykynurenine-0-beta-dl-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation | |
ES2275873T3 (es) | Composiciones orales para el tratamiento de mamiferos obesos y no diabeticos incluyendo humanos. | |
US20100227006A1 (en) | Powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis | |
WO2018039755A1 (pt) | Formulação farmacêutica a base de zinco e quercetina para a produção de medicação antiviral eficaz para dengue e zika | |
CN103405398B (zh) | 一种尿囊素制剂及其用途 | |
WO1988000048A1 (en) | Drug for prophylaxis and treatment of hepatopathy | |
ES2894115T3 (es) | Composición para suplementación de calcio | |
EP3678498B1 (en) | Composition for calcium supplementation | |
WO2012156502A2 (en) | Two component mouth rinse preparation | |
RU2798918C2 (ru) | Жидкая фармацевтическая комбинация октенидина гидрохлорида, феноксиэтанола и нестероидного противовоспалительного агента | |
ES2753814T3 (es) | Un procedimiento de tratamiento de urolitiasis y trastornos urológicos relacionados | |
RU2613765C1 (ru) | Способ лечения спиноцеребеллярной атаксии | |
US20230082870A1 (en) | Composition for calcium supplementation | |
WO2004012747A1 (ja) | 水分摂取量調整用噴霧剤 | |
Mak et al. | RENAL HYPERPHOSPHATEMIA | |
RU2280457C1 (ru) | Лекарственное средство для лечения железодефицитных анемий | |
WO2019150323A1 (en) | Sports supplements based on liquid creatine | |
WO2003000299A1 (en) | Laxative preparation | |
AUB et al. | FACTORS INFLUENCING THE RATE OF LEAD EXCRETION IN ANIMALS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/A/2003/010273 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2447141 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10477807 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002732763 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002732763 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002732763 Country of ref document: EP |